Alterola Biotech Inc. financial data

Symbol
ABTI on OTC
Industry
Medicinal Chemicals & Botanical Products
Location
47 Hamilton Square, Birkenhead Merseyside, United Kingdom
Fiscal year end
March 31
Former names
JEDEDIAH RESOURCES CORP. (to 11/19/2010)
Latest financial report
Q4 2023 - Feb 21, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 8.02 % -32.5%
Quick Ratio 0.05 % -40.5%
Debt-to-equity 49.7 % +269%
Return On Equity -67.3 % +9.57%
Return On Assets -44.9 % +32.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.38B shares
Common Stock, Shares, Outstanding 1.38B shares +71.3%
Entity Public Float 10.7M USD -93.5%
Common Stock, Value, Issued 1.38M USD +71.3%
Weighted Average Number of Shares Outstanding, Basic 803M shares +6.41%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.88K USD
General and Administrative Expense 89.1K USD +32.7%
Operating Income (Loss) -1.89M USD +62.9%
Net Income (Loss) Attributable to Parent -2.87M USD +64.4%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Inventory, Net 1.02K USD +4.96%
Assets, Current 3.59K USD -98.1%
Deferred Income Tax Assets, Net 187K USD +41.9%
Assets 3.59K USD -100%
Accounts Payable, Current 804K USD +20.2%
Accrued Liabilities, Current 311K USD +2398%
Liabilities, Current 1.36M USD -25.5%
Liabilities 1.36M USD -31.2%
Retained Earnings (Accumulated Deficit) -12.4M USD -30.2%
Stockholders' Equity Attributable to Parent -1.35M USD -113%
Liabilities and Equity 3.59K USD -100%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -75.5K USD +65.1%
Net Cash Provided by (Used in) Financing Activities 68.4K USD +33.2%
Net Cash Provided by (Used in) Investing Activities -18.9K USD
Common Stock, Shares Authorized 2B shares 0%
Common Stock, Shares, Issued 1.38B shares +71.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -25.9K USD +84.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.57K USD -79.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.02M USD -297%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -155K USD
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 9.66M USD -48.9%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense -38 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%